341 related articles for article (PubMed ID: 9664152)
21. Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma.
Girod SC; Pfeiffer P; Ries J; Pape HD
Br J Oral Maxillofac Surg; 1998 Aug; 36(4):252-60. PubMed ID: 9762452
[TBL] [Abstract][Full Text] [Related]
22. [Expression of bcl-2, Ki-67 and p-53 in uveal melanomas].
Krvavica A; Talan-Hranilović J; Belicza M
Acta Med Croatica; 2008 Jul; 62(3):267-71. PubMed ID: 18843846
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors.
Sparrow LE; English DR; Taran JM; Heenan PJ
Am J Dermatopathol; 1998 Feb; 20(1):12-6. PubMed ID: 9504663
[TBL] [Abstract][Full Text] [Related]
24. The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx.
Pignataro L; Capaccio P; Pruneri G; Carboni N; Buffa R; Neri A; Ottaviani A
J Laryngol Otol; 1998 May; 112(5):455-9. PubMed ID: 9747474
[TBL] [Abstract][Full Text] [Related]
25. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.
Chana JS; Wilson GD; Cree IA; Alexander RA; Myatt N; Neale M; Foss AJ; Hungerford JL
Br J Ophthalmol; 1999 Jan; 83(1):110-4. PubMed ID: 10209447
[TBL] [Abstract][Full Text] [Related]
26. [Survival of patients with laryngeal cancer and some prognostic factors].
Gryczyński M; Kobos J; Murlewska A; Pietruszewska W
Otolaryngol Pol; 2003; 57(3):329-40. PubMed ID: 14524174
[TBL] [Abstract][Full Text] [Related]
27. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma.
Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ
Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753
[TBL] [Abstract][Full Text] [Related]
28. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma.
Mäkinen K; Hakala T; Lipponen P; Alhava E; Eskelinen M
Anticancer Res; 1998; 18(1B):615-8. PubMed ID: 9568186
[TBL] [Abstract][Full Text] [Related]
29. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
31. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer.
Pinto AE; André S; Laranjeira C; Soares J
Pathology; 2005 Feb; 37(1):45-50. PubMed ID: 15875733
[TBL] [Abstract][Full Text] [Related]
32. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia.
Dellas A; Schultheiss E; Almendral AC; Gudat F; Oberholzer M; Feichter G; Moch H; Torhorst J
Int J Cancer; 1997 Aug; 74(4):421-5. PubMed ID: 9291432
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: a retrospective immunohistochemical analysis.
Masuda M; Takano Y; Iki M; Asakura T; Hashiba T; Noguchi S; Hosaka M
Pathol Int; 1998 Jan; 48(1):41-6. PubMed ID: 9589463
[TBL] [Abstract][Full Text] [Related]
34. Chromosomal abnormalities, p53 and Bcl-2 expression and clinical outcome in choroidal melanoma.
Erol N; Oner U; Artan S; Işiksoy S; Yurdakul S
Melanoma Res; 2004 Dec; 14(6):473-8. PubMed ID: 15577317
[TBL] [Abstract][Full Text] [Related]
35. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
36. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
37. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.
Antonescu CR; Leung DH; Dudas M; Ladanyi M; Brennan M; Woodruff JM; Cordon-Cardo C
Am J Pathol; 2000 Mar; 156(3):977-83. PubMed ID: 10702413
[TBL] [Abstract][Full Text] [Related]
38. [Gastric cancer and tumor growth regulation. Study of cell proliferation markers and protein complex p53/p21WAF1/CIP1/mdm-2].
Villaseca M; Araya JC; Roa I; Roa JC
Rev Med Chil; 2000 Feb; 128(2):127-36. PubMed ID: 10962880
[TBL] [Abstract][Full Text] [Related]
39. Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67.
Engellau J; Persson A; Bendahl PO; Akerman M; Domanski HA; Bjerkehagen B; Lilleng P; Weide J; Rydholm A; Alvegård TA; Nilbert M
Virchows Arch; 2004 Sep; 445(3):224-30. PubMed ID: 15309631
[TBL] [Abstract][Full Text] [Related]
40. Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2, Ki-67 and p53.
Meara RS; Cangiarella J; Simsir A; Horton D; Eltoum I; Chhieng DC
Cytopathology; 2007 Oct; 18(5):283-9. PubMed ID: 17883690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
